CN104203906B - 间位取代的联苯基外周限制性faah抑制剂 - Google Patents

间位取代的联苯基外周限制性faah抑制剂 Download PDF

Info

Publication number
CN104203906B
CN104203906B CN201280051448.5A CN201280051448A CN104203906B CN 104203906 B CN104203906 B CN 104203906B CN 201280051448 A CN201280051448 A CN 201280051448A CN 104203906 B CN104203906 B CN 104203906B
Authority
CN
China
Prior art keywords
compound
pain
faah
pharmaceutical composition
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201280051448.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN104203906A (zh
Inventor
D·皮翁梅利
G·莫雷诺-桑斯
T·班迪耶拉
M·莫尔
G·塔尔齐亚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universita Degli Di Parma
University of Urbino
Italian Institute of Technology
University of California, San Diego
Original Assignee
Universita Degli Di Parma
University of Urbino
Italian Institute of Technology
University of California, San Diego
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universita Degli Di Parma, University of Urbino, Italian Institute of Technology, University of California, San Diego filed Critical Universita Degli Di Parma
Publication of CN104203906A publication Critical patent/CN104203906A/zh
Application granted granted Critical
Publication of CN104203906B publication Critical patent/CN104203906B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/56—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/02—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups from isocyanates with formation of carbamate groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201280051448.5A 2011-08-19 2012-08-17 间位取代的联苯基外周限制性faah抑制剂 Active CN104203906B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161525636P 2011-08-19 2011-08-19
US61/525,636 2011-08-19
PCT/US2012/051478 WO2013028570A2 (en) 2011-08-19 2012-08-17 Meta-substituted biphenyl peripherally restricted faah inhibitors

Publications (2)

Publication Number Publication Date
CN104203906A CN104203906A (zh) 2014-12-10
CN104203906B true CN104203906B (zh) 2018-03-13

Family

ID=47747054

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280051448.5A Active CN104203906B (zh) 2011-08-19 2012-08-17 间位取代的联苯基外周限制性faah抑制剂

Country Status (12)

Country Link
US (1) US9745255B2 (cg-RX-API-DMAC10.html)
EP (1) EP2744778B1 (cg-RX-API-DMAC10.html)
JP (1) JP6092870B2 (cg-RX-API-DMAC10.html)
KR (1) KR102079404B1 (cg-RX-API-DMAC10.html)
CN (1) CN104203906B (cg-RX-API-DMAC10.html)
AU (1) AU2012299060B2 (cg-RX-API-DMAC10.html)
BR (1) BR112014003886B1 (cg-RX-API-DMAC10.html)
CA (1) CA2844812C (cg-RX-API-DMAC10.html)
DK (1) DK2744778T3 (cg-RX-API-DMAC10.html)
ES (1) ES2708723T3 (cg-RX-API-DMAC10.html)
MX (1) MX354772B (cg-RX-API-DMAC10.html)
WO (1) WO2013028570A2 (cg-RX-API-DMAC10.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100485727B1 (ko) * 2004-06-24 2005-04-27 주식회사 바이오리더스 폴리감마글루탐산-비타민 복합체 및 그 용도
JP6092870B2 (ja) 2011-08-19 2017-03-08 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア メタ置換ビフェニル末梢に限局されたｆａａｈ阻害剤
WO2014023325A1 (en) * 2012-08-06 2014-02-13 Fondazione Istituto Italiano Di Tecnologia Multitarget faah and cox inhibitors and therapeutical uses thereof
ES2908240T3 (es) * 2014-04-07 2022-04-28 Univ California Inhibidores de la enzima amida hidrolasa de ácidos grasos (FAAH) con biodisponibilidad oral mejorada y su uso como medicamentos
WO2017025588A1 (en) * 2015-08-11 2017-02-16 Eyesiu Medicines B.V. Pegylated lipid nanoparticle with bioactive lipophilic compound
CN109414596B (zh) * 2016-05-12 2023-09-29 密歇根大学董事会 Ash1l抑制剂和用其进行治疗的方法
SG10201802129QA (en) 2017-07-05 2019-02-27 Frimline Private Ltd A pharmaceutical composition for neuropathic pain
US10702487B2 (en) 2017-08-19 2020-07-07 Frimline Private Limited Pharmaceutical composition for prevention of diet induced obesity
PH12018000227B1 (en) 2017-09-05 2019-03-11 Frimline Private Ltd A pharmaceutical composition for improving or preventing progression of chronic kidney disease
GB201802326D0 (en) 2018-02-13 2018-03-28 Ucl Business Plc Gene therapy
ES3053087T3 (en) 2018-03-05 2026-01-19 Wylder Nation Found A fatty acid amide hydrolase (faahi) inhibitor for use in inhibiting the cellular accumulation of a sphingolipid in a subject that has lysosomal storage disease or disorder
CA3125980A1 (en) * 2019-01-10 2020-07-16 Travecta Therapeutics Pte. Ltd. Anandamide compounds
US20230313196A1 (en) * 2020-07-23 2023-10-05 John Mansell Compositions and methods for treating pain and anxiety disorders
CN120965462B (zh) * 2025-10-17 2026-02-17 四川奥邦古得药业有限公司 用于生产3,5-二醚戊苯的方法及其在制备3,5-二羟基戊苯中的应用
CN121342719A (zh) * 2025-10-17 2026-01-16 成都奥邦药业有限公司 一种式5所示和2的化合物的制备方法以及大麻二酚的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1729171A (zh) * 2002-10-07 2006-02-01 加利福尼亚大学董事会 通过阻断花生四烯酰乙醇酰胺的水解调节焦虑
WO2008063714A1 (en) * 2006-11-20 2008-05-29 N.V. Organon Metabolically-stabilized inhibitors of fatty acid amide hydrolase

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4325889A (en) 1978-08-04 1982-04-20 Bayer Aktiengesellschaft Process for the preparation of 1-amino-8-naphthol-3,6-disulphonic acid (H-acid)
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4511503A (en) 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US5541061A (en) 1992-04-29 1996-07-30 Affymax Technologies N.V. Methods for screening factorial chemical libraries
DE69314148T2 (de) 1992-12-17 1998-01-15 Valeo Systemes Essuyage Stromversorgungsverfahren und -vorrichtung für einen elektrischen Motor zum Antrieb eines Scheibenwischers eines Kraftfahrzeugs
US5576220A (en) 1993-02-19 1996-11-19 Arris Pharmaceutical Corporation Thin film HPMP matrix systems and methods for constructing and displaying ligands
US6271015B1 (en) 1995-06-12 2001-08-07 The Scripps Research Institute Fatty-acid amide hydrolase
CA2206192A1 (en) 1996-06-13 1997-12-13 F. Hoffmann-La Roche Ag Modulation of lc132 (opioid-like) receptor function
WO1998024443A1 (en) 1996-12-02 1998-06-11 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating bipolar disorders
GB9701453D0 (en) 1997-01-24 1997-03-12 Leo Pharm Prod Ltd Aminobenzophenones
FR2758723B1 (fr) 1997-01-28 1999-04-23 Sanofi Sa Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
TW492882B (en) 1997-11-28 2002-07-01 Caleb Pharmaceuticals Inc Cholinergic antagonist plaster composition
US6281243B1 (en) 1998-02-26 2001-08-28 Akzo Nobel N.V. Derivatives of azetidine and pyrrolidine
CA2330681C (en) 1998-05-29 2008-08-26 Andrea Giuffrida Control of pain with endogenous cannabinoids
US7897598B2 (en) 1998-06-09 2011-03-01 Alexandros Makriyannis Inhibitors of the anandamide transporter
US20030134894A1 (en) 1999-04-07 2003-07-17 Daniele Piomelli Methods of treating mental diseases, inflammation and pain
US6261595B1 (en) 2000-02-29 2001-07-17 Zars, Inc. Transdermal drug patch with attached pocket for controlled heating device
NZ570989A (en) 2002-05-16 2010-01-29 Sepracor Inc Amines that inhibit a mammalian anandamide transporter, and methods of use thereof
FR2842808B1 (fr) 2002-07-25 2004-09-10 Sod Conseils Rech Applic Nouveaux derives d'arylimidazoles, leur preparation et leurs applications therapeutiques
FR2850377B1 (fr) 2003-01-23 2009-02-20 Sanofi Synthelabo Derives d'arylalkylcarbamates, leur preparation et leur application en therapeutique
FR2866888B1 (fr) 2004-02-26 2006-05-05 Sanofi Synthelabo Derives de alkylpiperazine- et alkylhomopiperazine- carboxylates, leur preparation et leur application en therapeutique
US20070155707A1 (en) 2005-12-29 2007-07-05 Kadmus Pharmaceuticals, Inc. Ionizable inhibitors of fatty acid amide hydrolase
US9316633B2 (en) 2006-11-16 2016-04-19 The Regents Of The University Of California Methods for identifying inhibitors of solute transporters
TW200948805A (en) 2008-03-07 2009-12-01 Sigma Tau Ind Farmaceuti Enol carbamate derivatives as modulators of fatty acid amide hydrolase
ES2749504T3 (es) 2009-10-13 2020-03-20 Ligand Pharm Inc Compuestos de moléculas pequeñas miméticos del factor de crecimiento hematopoyético y sus usos
EP2598477B1 (en) 2010-07-28 2016-03-02 The Regents of The University of California Peripherally restricted faah inhibitors
WO2012167133A2 (en) 2011-06-01 2012-12-06 The Regents Of The University Of California Inhibitors of anandamide transport and their therapeutic uses
JP6092870B2 (ja) 2011-08-19 2017-03-08 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア メタ置換ビフェニル末梢に限局されたｆａａｈ阻害剤
ES2908240T3 (es) 2014-04-07 2022-04-28 Univ California Inhibidores de la enzima amida hidrolasa de ácidos grasos (FAAH) con biodisponibilidad oral mejorada y su uso como medicamentos

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1729171A (zh) * 2002-10-07 2006-02-01 加利福尼亚大学董事会 通过阻断花生四烯酰乙醇酰胺的水解调节焦虑
US20090048337A1 (en) * 2002-10-07 2009-02-19 The Regents Of The University Of California Modulation of anxiety through blockade of anandamide hydrolysis
WO2008063714A1 (en) * 2006-11-20 2008-05-29 N.V. Organon Metabolically-stabilized inhibitors of fatty acid amide hydrolase

Also Published As

Publication number Publication date
WO2013028570A3 (en) 2013-04-18
MX2014001966A (es) 2015-04-08
MX354772B (es) 2018-03-21
US20140288170A1 (en) 2014-09-25
NZ622480A (en) 2016-05-27
HK1198644A1 (en) 2015-05-22
JP2014527532A (ja) 2014-10-16
ES2708723T3 (es) 2019-04-10
WO2013028570A2 (en) 2013-02-28
CN104203906A (zh) 2014-12-10
AU2012299060B2 (en) 2017-06-01
EP2744778A4 (en) 2015-04-08
AU2012299060A1 (en) 2014-04-03
BR112014003886B1 (pt) 2022-04-19
JP6092870B2 (ja) 2017-03-08
EP2744778A2 (en) 2014-06-25
BR112014003886A8 (pt) 2018-01-23
EP2744778B1 (en) 2019-01-16
CA2844812A1 (en) 2013-02-28
US9745255B2 (en) 2017-08-29
DK2744778T3 (en) 2019-03-04
CA2844812C (en) 2019-10-22
KR102079404B1 (ko) 2020-02-19
KR20150100485A (ko) 2015-09-02
BR112014003886A2 (pt) 2017-03-21

Similar Documents

Publication Publication Date Title
EP2744778B1 (en) Meta-substituted biphenyl peripherally restricted faah inhibitors
CN103153946B (zh) 外周限制性 faah 抑制剂
US10538790B2 (en) Bioenzymatic synthesis of THC-v, CBV and CBN and their use as therapeutic agents
US10384997B2 (en) Bio-stable cannabinoid compounds and methods for enhancing their physiological concentration
US20160235707A1 (en) Disubstituted beta-lactones as inhibitors of n-acylethanolamine acid amidase (naaa)
CN113233996B (zh) 新型trpv1拮抗/faah抑制双靶点药物及其制备方法和应用
CN106562951B (zh) 一种呋喃类d-3-磷酸甘油酸脱氢酶别构抑制剂及其应用
CN113461563B (zh) Nqo1激活型6-重氮基-5-氧代-l-正亮氨酸前药及其制备方法和应用
TW201922690A (zh) 環－amp反應元素結合蛋白的抑制劑
HK1198644B (en) Meta-substituted biphenyl peripherally restricted faah inhibitors
RS53747B1 (sr) Jedinjenja fenantrenona, kompozicije i metode
NZ622480B2 (en) Meta-substituted biphenyl peripherally restricted faah inhibitors
WO2018076537A1 (zh) D-3-磷酸甘油酸脱氢酶别构抑制剂及其应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant